HITHIUM
9.7.2024 12:43:27 CEST | Business Wire | Press release
Stationary battery manufacturer Hithium has successfully deployed the largest battery energy storage system (BESS) project in Eastern Europe to date, with a capacity of 55MWh. This solar plus storage project was realized completely by EPC company Solarpro, in Razlog, Southwestern Bulgaria, where the project is located.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709299471/en/
Hithium BESS project in Razlog, Bulgaria (Photo: Business Wire)
The new facility officially went live in early June, with the delivery of Hithium’s 16 energy storage containers, each with a capacity of 3.44MWh, to Solarpro. Solarpro is a leading technological provider of solutions for the generation and storage of energy within whole Europe.
Hithium ∞ Block 3.44MWh container
The Hithium ∞ Block 3.44MWh container is a liquid-cooled battery storage system based on Hithium prismatic LFP BESS cells with a 280Ah capacity and a high cyclic lifetime. It is specially optimized for use in stationary battery storage systems with high standards of safety, reliability, and performance. The system’s low levelized cost of storage (LCOS), combined with excellent thermal management, improves energy throughput by ensuring optimal operating temperature and high energy density. It also integrates with a thermal management system, fire protection system, battery management system (BMS), and more.
As Kelson Li, Hithium Senior Director of Sales of DACH, Northern & Eastern Europe said: "We are honored to partner with Solarpro. By providing comprehensive technical and after-sales support throughout the project lifecycle, we aim to foster local expertise and expand the network in Europe. We believe our collaboration with Solarpro will help to accelerate the renewable energy transition and make a positive impact in the region."
Krasen Mateev, CEO of Solarpro adds: "As strategic partners in this landmark project, we are excited to collaborate with Hithium in bringing this significant BESS utility to operation. This undertaking reflects Solarpro’s dedication to advance renewable energy infrastructure in Eastern Europe, ensuring a sustainable energy future for generations to come."
Hithium’s Commitment to the European Market
Hithium is committed to fostering a stronger and more collaborative relationship within the local European market. To this end, the company has set up a regional office in Munich, Germany, offering local support and services. Furthermore, Hithium has formed strategic alliances with other industry leaders, including Scan Global Logistics, to offer unparalleled transportation services, and CarbonX, to advance the energy sector in terms of environmental responsibility and technological advancement.
About Hithium
Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With more than 20GWh BESS projects shipment up to date. Hithium took the top 5 global market shares and was ranked as the Tier 1 BESS supplier. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California.
About Solarpro
Solarpro is a multi-technology integrator with expertise in hybrid projects that include photovoltaic (PV), wind, battery energy storage systems (BESS), and hydrogen solutions. As a leading EPC contractor with 15 years of experience and a team of over 1,000 professionals, Solarpro has designed, built, and integrated PV plants with a total capacity exceeding 7 GW. The company is a technological innovator, excelling in engineering and digitalizing renewable projects, transforming them into dispatchable and flexible assets aligned with energy market developments. Committed to sustainability, Solarpro has further developed expertise in recycling PV modules and batteries to utilize damaged or polluted land, transforming them into state-of-the-art clean energy plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709299471/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom